drug_type
RELEVANT_DRUG
intervention_type
Biological: gene-modified cellular immunotherapy
drug_description
Natural killer cells genetically engineered to express a chimeric antigen receptor to enhance antigen-specific cytotoxicity; given as a single IV infusion (~1–2×10^6 cells/kg) following lymphodepleting chemotherapy. Mechanism: CAR-mediated target recognition combined with innate NK cytotoxic pathways (perforin/granzyme, Fas/TRAIL).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor-Modified NK Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
NK cells are genetically engineered to express a chimeric antigen receptor that enables antigen-specific, MHC-independent recognition of tumor cells. CAR engagement activates NK signaling and enhances innate NK cytotoxic mechanisms, leading to target-cell killing via perforin/granzyme release and death-receptor pathways (Fas/TRAIL), along with cytokine secretion to eliminate antigen-expressing tumor cells.
drug_name
CAR-NK cell therapy
nct_id_drug_ref
NCT06572956